Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata

In Kwon Yeo, Eun Jung Ko, Yeon A No, Ee Seok Lim, Kui Young Park, Kapsok Li, Beom Joon Kim, Seong Jun Seo, Myeung Nam Kim, Chang Kwun Hong

Department of Dermatology, Chung-Ang University College of Medicine, 1Theme Skin Clinic, Seoul, Korea

Background: Severe alopecia areata (AA) is resistant to conventional treatment. Although systemic oral corticosteroids are an effective treatment for patients with severe AA, those drugs have many adverse effects. Corticosteroid pulse therapy has been introduced to increase therapeutic effects and reduce adverse effects. However, the treatment modality in severe AA is still controversial. Objective: To evaluate the effectiveness of corticosteroid pulse therapy in patients with severe AA compared with treatment with oral cyclosporine with corticosteroid. Methods: A total of 82 patients with severe AA were treated with corticosteroid pulse therapy, and 60 patients were treated with oral cyclosporine with corticosteroid. Both groups were retrospectively evaluated for therapeutic efficacy according to AA type and disease duration. Results: In 82 patients treated with corticosteroid pulse therapy, 53 (64.6%) were good responders (>50% hair regrowth). Patients with the plurifocal (PF) type of AA and those with a short disease duration (≤3 months) showed better responses. In 60 patients treated with oral cyclosporine with corticosteroid, 30 (50.0%) patients showed a good response. The AA type or disease duration, however, did not significantly affect the response to treatment. Conclusion: Corticosteroid pulse therapy may be a better treatment option than combination therapy in severe AA patients with the PF type. (Ann Dermatol 27(6) 676∼681, 2015)

Keywords: Alopecia areata, Cyclosporine, Pulse therapy

INTRODUCTION

Alopecia areata (AA) is a relatively common non-scarring hair loss disorder. Approximately 0.2% of the population has AA, and approximately 1.7% of the population will experience an episode of AA during their lifetime. Although the exact etiology of AA is still unknown, evidence indicates that it may have an autoimmune basis. Whereas patients with mild to moderate AA have a high rate of spontaneous recovery, severe AA is a refractory condition. Severe AA does not usually respond to conventional treatments, including topical, intralesional, and systemic steroids; topical sensitizers; anthralin; minoxidil; and photochemotherapy.

Among these treatments, systemic oral corticosteroids have been reported to be effective in patients with extensive AA. Relapse after dose reduction and other adverse effects during long-term therapy, however, have restricted the use of systemic oral corticosteroids. Burton and Shuster introduced corticosteroid pulse therapy for treating AA to increase therapeutic effects and reduce adverse effects. Since then, physicians have tried a range of doses in corticosteroid pulse therapy. Cyclosporine, which is commonly used as an immunomodulatory agent, has a common adverse effect of dose-dependent hypertrichosis. It also decreases the perifollicular lymphocytic infiltrates. Several studies have shown that the combination therapy of cyclosporine and corticosteroid may be
a useful treatment for severe AA\textsuperscript{13,14}.

The aim of this study was to evaluate the effectiveness of high-dose corticosteroid pulse therapy compared with the combination therapy of oral cyclosporine and low-dose corticosteroid in patients with severe AA.

**MATERIALS AND METHODS**

In this study, 142 patients who presented at the Department of Dermatology, Chung-Ang University Hospital, between January 2009 and September 2012, with extensive AA lesions were retrospectively evaluated. A total of 82 patients with severe AA were treated with high-dose corticosteroid pulse therapy, and 60 patients were treated with oral cyclosporine with low-dose corticosteroid. The inclusion criteria were as follows: (i) plurifocal (PF) alopecia (with a bald surface exceeding 30\% of the scalp), alopecia totalis (AT; with a complete absence of terminal scalp hair), and alopecia universalis (AU; with a total loss of terminal scalp and body hair); and (ii) present activity of the disease clinically corresponding to ongoing hair loss and/or histologically indicated by a perifollicular lymphocytic infiltrate in biopsies of lesional skin\textsuperscript{15,16}.

Before treatment, a complete physical examination and laboratory testing, including complete blood cell count, erythrocyte sedimentation rate, high-sensitive C-reactive protein, electrolyte, liver function test, renal function test, antithyroglobulin antibody, antinuclear antibody, electrocardiography, and chest radiography, were performed. Patients in the corticosteroid pulse therapy group were admitted to the hospital and treated with methylprednisolone, by using an intravenous infusion pump, at a dose of 30 mg/day for 3 days. The dose was then tapered to 2.5 mg/day for 2 weeks to avoid steroid withdrawal symptoms. The combination therapy of oral cyclosporine and methylprednisolone was gradually tapered, and the drugs were eventually discontinued. Blood pressure, pulse rate, and blood parameters (e.g., renal function test) were regularly measured.

We examined patient characteristics such as sex, age, type of AA, and duration of disease before treatment; evaluated the therapeutic efficacy at 6 months by using the clinical record and photographs; and investigated the adverse effects after treatment. Hair growth was assessed on a percentage scale, ranging from 0\% to 100\% of regrowth in AA lesions. To observe the association with AA type or duration for the treatment response, we further divided the patients into five groups according to hair regrowth. Only growth of terminal hair from the lesions was considered as regrowth (grade 1: 0\% - 24\%, grade 2: 25\% - 49\%, grade 3: 50\% - 74\%, grade 4: 75\% - 99\%, and grade 5: 100\% improvement). For other correlative analyses, we considered regrowth on >50\% of the lesional surface as a “good response.” During follow-up, a hair loss of >25\% was considered a relapse. Statistical analysis was performed using SPSS version 12.0 for Windows statistical package (SPSS Inc., Chicago, IL, USA). Analysis of variance and Mann-Whitney U test were used. A \( p < 0.05 \) was considered as statistically significant. This study was approved by the institutional review board of Chung-Ang University Hospital, Seoul, Korea (IRB No. C2015015[1473]).

**RESULTS**

**Patient characteristics**

The study consisted of 79 men and 63 women with an age range of 8~80 years (mean, 35.1 years). Twenty-seven (19.0\%) of the 142 patients had a family history of AA. The prevalence of the AA type was observed in the following order in both the corticosteroid pulse therapy group and the combination therapy group: PF (68.3\%) > AT (18.3\%) > AU (13.4\%). The mean duration before treatment was 18.6 months (range, 1 month to 24 years; Table 1).

**Therapeutic effect**

In 82 patients treated with high-dose corticosteroid pulse therapy, 53 (64.6\%) were good responders. According to AA types, the PF group showed a better response than the AT or AU group (PF vs. AT, \( p = 0.048 \); PF vs. AU, \( p = 0.021 \)). In the recent-onset group (duration of AA \( \leq 3 \) months), 85.7\% of the patients were good responders; in the other groups according to onset, 65.0\% (4~6 months), 50.0\% (7~12 months), and 45.5\% (\( \geq 13 \) months) of patients showed a good response. There was a statistically significant difference between the \( \leq 3 \)-month group and the \( > 13 \)-month group (\( p = 0.017 \); Fig. 1). The outcomes did not differ significantly between any of the other groups.

In the 60 patients treated with oral cyclosporine with low-dose corticosteroid, 30 patients (50.0\%) showed a good response. Similar to the patients treated with pulse therapy, the PF group showed a better response than the
other groups. In addition, the recent-onset group showed a better response than the other groups. The differences, however, were not statistically significant (Fig. 2).

In the comparison of therapeutic efficacy between corticosteroid pulse therapy and combination therapy of oral cyclosporine and corticosteroid, 77.4% of patients with the PF type of AA treated with corticosteroid pulse therapy were good responders, in contrast to 52.3% of the patients with the PF type of AA treated with the combination therapy ($p=0.009$; Table 2, Fig. 3). The patients treated with corticosteroid pulse therapy had better outcomes than those treated with the combination therapy in the ≤3-month group, the 4- to 6-month group, and the ≥13-month group.

**Relapse rate**

Although the patients were followed from 6 to 48 months after treatment, relapse of AA lesions occurred in 11 of the 55 (20.0%) good responders in the steroid pulse therapy group and 8 of the 30 (26.7%) good responders in the combination therapy group. However, there was no statistically significant difference.

**Adverse effects**

Adverse effects, including gastrointestinal discomfort, headache, dizziness, facial flushing, and palpitation, were observed in 16 patients (19.5%) in the steroid pulse therapy group. In the combination therapy group, adverse effects, including gastrointestinal discomfort, headache, and hypertension, were observed in 11 patients (18.3%). None of the patients, however, had serious adverse effects requiring cessation of treatment.

**DISCUSSION**

There is increasing evidence that AA is likely a tissue-specific autoimmune disease. Hair follicle-specific IgG autoantibodies have been found in the peripheral blood of AA patients. The presence of inflammatory lymphocytes around affected hair follicles on biopsy of AA lesions also supports the autoimmune hypothesis. Several treatment modalities have been described involving an immuno-

---

**Table 1. Patient characteristics**

| Characteristic      | High-dose corticosteroid pulse therapy (%) | Oral cyclosporine with low-dose corticosteroid therapy (%) | $p$-value |
|---------------------|-------------------------------------------|-------------------------------------------------------------|-----------|
| Sex                 |                                           |                                                             | 0.248     |
| Male                | 49 (59.8)                                 | 30 (50.0)                                                   |           |
| Female              | 33 (40.2)                                 | 30 (50.0)                                                   |           |
| Age (yr)            |                                           |                                                             | 0.290     |
| <20                 | 10 (12.2)                                 | 2 (3.3)                                                     |           |
| 20∼29               | 21 (25.6)                                 | 21 (35.0)                                                   |           |
| 30∼39               | 25 (30.5)                                 | 15 (25.0)                                                   |           |
| 40∼49               | 13 (15.9)                                 | 10 (16.7)                                                   |           |
| ≥50                 | 13 (15.9)                                 | 12 (20.0)                                                   |           |
| Mean                | 34.1                                      | 36.4                                                        |           |
| Family history      |                                           |                                                             | 0.542     |
| Yes                 | 17 (20.1)                                 | 10 (16.7)                                                   |           |
| No                  | 38 (48.0)                                 | 22 (36.7)                                                   |           |
| Type                |                                           |                                                             | 0.491     |
| Plurifocal          | 53 (64.6)                                 | 44 (73.3)                                                   |           |
| Alopecia totalis    | 16 (19.5)                                 | 10 (16.7)                                                   |           |
| Alopecia universalis| 13 (15.9)                                 | 6 (10.0)                                                    |           |
| Duration (mo)       |                                           |                                                             | 0.806     |
| ≤3                  | 28 (34.1)                                 | 21 (35.0)                                                   |           |
| 4∼6                 | 20 (24.4)                                 | 17 (28.3)                                                   |           |
| 7∼12                | 12 (14.6)                                 | 10 (16.7)                                                   |           |
| ≥13                 | 22 (26.8)                                 | 12 (20.0)                                                   |           |

---

**Fig. 1.** Comparison of outcomes at 6 months after corticosteroid pulse therapy according to (A) alopecia areata type and (B) duration ($^{*}p<0.05$, as determined by using ANOVA with post hoc Tukey analysis). PF: plurifocal, AT: alopecia totalis, AU: alopecia universalis.
Table 2. Treatment response to high-dose corticosteroid pulse therapy, oral cyclosporine, and low-dose corticosteroid therapy in severe alopecia patients

| Treatment Type                        | No. of patients | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---------------------------------------|-----------------|---------|---------|---------|---------|---------|
| High-dose corticosteroid pulse therapy| 82              | 16      | 13      | 16      | 21      | 16      |
| Type                                  |                 |         |         |         |         |         |
| Plurifocal                            | 53              | 4       | 8       | 12      | 17      | 12      |
| Alopecia totalis                      | 16              | 7       | 2       | 2       | 2       | 3       |
| Alopecia universalis                  | 13              | 5       | 3       | 2       | 2       | 1       |
| Duration (mo)                         |                 |         |         |         |         |         |
| ≤3                                    | 28              | 2       | 2       | 5       | 11      | 8       |
| 4~6                                   | 20              | 6       | 1       | 4       | 5       | 4       |
| 7~12                                  | 12              | 2       | 4       | 3       | 2       | 1       |
| ≥13                                   | 22              | 6       | 6       | 4       | 3       | 3       |
| Oral cyclosporine with low-dose corticosteroid therapy | 60 | 12 | 18 | 16 | 11 | 3 |
| Type                                  |                 |         |         |         |         |         |
| Plurifocal                            | 44              | 9       | 12      | 13      | 7       | 3       |
| Alopecia totalis                      | 10              | 2       | 4       | 2       | 2       | 0       |
| Alopecia universalis                  | 6               | 1       | 2       | 1       | 2       | 0       |
| Duration (mo)                         |                 |         |         |         |         |         |
| ≤3                                    | 21              | 5       | 2       | 8       | 5       | 1       |
| 4~6                                   | 17              | 4       | 5       | 4       | 4       | 0       |
| 7~12                                  | 10              | 1       | 4       | 2       | 1       | 2       |
| ≥13                                   | 12              | 2       | 7       | 2       | 1       | 0       |

Grade 1: 0%~24%, grade 2: 25%~49%, grade 3: 50%~74%, grade 4: 75%~99%, grade 5: 100% improvement (regrowth on >50% of the lesional surface as a good response).

modulatory mechanism.

In 1975, Burton and Shuster9 first introduced corticosteroid pulse therapy in treating AA to avoid the adverse effects of prolonged corticosteroid therapy. The clinical response was poor because of inappropriate dosage and the selection of patients with chronic severe AA. Since then, many studies have tried to induce AA remission with corticosteroid pulse therapy. The advantages of corticosteroid pulse therapy include fully ligand-occupied glucocorticoid receptors, nongenomic actions, including membrane-bound glucocorticoid receptor-mediated signaling, and direct physicochemical actions on the plasma membrane19. In addition, high corticosteroid levels may help correct the cytokine imbalance systemically or locally.

The standard dose of corticosteroid pulse therapy is unclear. Various treatment protocols have been used, such
Fig. 3. Comparison of therapeutic efficacy of corticosteroid pulse therapy and combination therapy of oral cyclosporine and corticosteroid (*p<0.05, as determined by using the Mann-Whitney U test). PF: plurifocal, AT: alopecia totalis, AU: alopecia universalis.

Concerning the therapeutic efficacy of corticosteroid pulse therapy compared with that of combination therapy, the treatment responses were not significantly different. The relapse rates of both groups were also not significantly different. Interestingly, however, AA patients with the PF type had significantly better responses to corticosteroid pulse therapy. It was difficult to directly compare this study with previous studies because of the different treatment protocols and patient selection methods. The difference of therapeutic effects compared with previous studies might also be due to the difference of the criteria for good response and the small sample size.

None of the patients in either therapeutic modality had serious adverse effects. Particularly, pulse corticosteroid therapy was tolerable in children. Some previous studies had excluded children because of possible adverse effects such as growth retardation. Tsai et al. however, administered corticosteroids to children <12 years of age, with 5 mg/kg oral prednisolone in three divided doses. Assouly et al. administrated 500-mg intravenous methylprednisolone daily for 3 consecutive days or 5-mg/kg intravenous methylprednisolone twice daily for 3 consecutive days in children. In the present study, we administered treatment to four children at a dose of 10 mg/kg weekly for 3 weeks, and no adverse effects were noted.

In conclusion, our study compares the therapeutic efficacy of corticosteroid pulse therapy and the combination therapy of oral cyclosporine and corticosteroid for severe AA patients. Corticosteroid pulse therapy seems to be effective in severe AA patients treated within 3 months of disease onset and severe AA patients with the PF type. Especially in severe AA patients with the PF type, corticosteroid pulse therapy may be a better treatment option than

one course of either 8 mg/(kg • day), 500 mg/day, or 1 g/day methylprednisolone for 3 consecutive days. The dosage of methylprednisolone administered in this study was 1 g/day for 3 consecutive days to achieve the maximum plasma concentration. We only performed one course of treatment because it has been shown that multiple courses have no benefit. In our study, 64.6% of the patients were good responders who showed regrowth on >50% of the lesional surface. This therapeutic effect was similar to that in patients with severe AA in previous studies. Some studies have evaluated the prognostic factors for the outcome of corticosteroid pulse therapy. Im et al. reported that patients with a disease duration of <6 months and the PF type had better responses to treatment. Seiter et al. also suggest that corticosteroid pulse therapy may be a better treatment option for the PF type but not for ophiasic AA, AT, or AU. Similar to these studies, we observed a better response in patients with a disease duration of <3 months and those with the PF type.

Cyclosporine is a common therapeutic agent used in patients who had received organ transplants; this drug selectively and reversibly inhibits the T-cell-mediated immune response. However, a common cutaneous adverse effect of cyclosporine is dose-dependent hypertrichosis due to the prolongation of the anagen phase of the hair cycle. Because corticosteroids are immunosuppressive agents that inhibit the late-phase antigen-dependent inflammatory reaction, combination therapy with cyclosporine as an early immunomodulator at the induction phase may have synergistic effects on immunosuppression.
REFERENCES

1. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992;128:702.
2. Price VH. Alopecia areata: clinical aspects. J Invest Dermatol 1991;96:685.
3. Shapiro J. Alopecia areata. Update on therapy. Dermatol Clin 1993;11:35-46.
4. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG; British Association of Dermatologists. Guidelines for the management of alopecia areata. Br J Dermatol 2003;149:692-699.
5. Fiedler VC. Alopecia areata. A review of therapy, efficacy, safety, and mechanism. Arch Dermatol 1992;128:1519-1529.
6. Lebwohl M. New treatments for alopecia areata. Lancet 1997;349:222-223.
7. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000;42:549-566.
8. Winter RJ, Kern F, Blizzard RM. Prednisone therapy for alopecia areata. A follow-up report. Arch Dermatol 1976;112:1549-1552.
9. Burton JL, Shuster S. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol 1975;55:493-496.
10. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-1738.
11. Taylor M, Ashcroft AT, Messenger AG. Cyclosporin A prolongs human hair growth in vitro. J Invest Dermatol 1993;100:237-239.
12. Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990;126:339-350.
13. Kim BJ, Min SU, Park KY, Choi JW, Park SW, Youn SW, et al. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat 2008;19:216-220.
14. Shapiro J, Lui H, Tron V, Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1997;36:114-117.
15. Friedli A, Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998;39:597-602.
16. Seiter S, Uguere S, Tilgen W, Reinhold U. High-dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatology 2001;202:230-234.
17. Lu W, Shapiro J, Yu M, Barekatain A, Lo B, Finner A, et al. Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med 2006;8:1-19.
18. McElwee KJ, Tobin DJ, Bystryn JC, King LE Jr, Sundberg JP. Alopecia areata: an autoimmune disease? Exp Dermatol 1999;8:371-379.
19. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998;41:761-767.
20. Im M, Lee SS, Lee Y, Kim CD, Seo YJ, Lee JH, et al. Prognostic factors in methylprednisolone pulse therapy for alopecia areata. J Dermatol 2011;38:767-772.
21. Nakajima T, Inui S, Itami S. Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatology 2007;215:320-324.
22. Assouly P, Reygagne P, Jouanique C, Matard B, Marechal E, Reynert P, et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata: an open study of 66 patients. Ann Dermatol Venereol 2003;130:326-330.
23. Ferron GM, Pyszczynski NA, Jusko WJ. Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays. Transplantation 1998;65:1203-1209.
24. Teshima H, Urabe A, Irie M, Nakaoka A, Nakayama J, Hori Y. Alopecia universalis treated with oral cyclosporine A and prednisolone: immunologic studies. Int J Dermatol 1992;31:513-516.
25. Tsai YM, Chen W, Hsu ML, Lin TK. High-dose steroid pulse therapy for the treatment of severe alopecia areata. J Formos Med Assoc 2002;101:223-226.